Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 20.9% in February

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the target of a significant growth in short interest in February. As of February 13th, there was short interest totaling 82,140 shares, a growth of 20.9% from the January 29th total of 67,935 shares. Based on an average daily volume of 51,786 shares, the short-interest ratio is presently 1.6 days. Approximately 1.7% of the shares of the company are sold short. Approximately 1.7% of the shares of the company are sold short. Based on an average daily volume of 51,786 shares, the short-interest ratio is presently 1.6 days.

Analysts Set New Price Targets

A number of analysts recently issued reports on EVAX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Maxim Group assumed coverage on Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Evaxion A/S currently has a consensus rating of “Moderate Buy” and an average price target of $11.75.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Evaxion A/S during the fourth quarter worth $38,000. Wesbanco Bank Inc. acquired a new position in Evaxion A/S in the 4th quarter valued at $48,000. Finally, SmartHarvest Portfolios LLC purchased a new position in Evaxion A/S during the 4th quarter worth $72,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Stock Down 1.6%

NASDAQ EVAX opened at $3.12 on Wednesday. The firm has a market cap of $26.02 million, a P/E ratio of -8.00 and a beta of 0.28. Evaxion A/S has a 52-week low of $1.20 and a 52-week high of $12.15. The business’s 50-day moving average price is $4.01 and its 200 day moving average price is $4.62.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.